|
|
 | | | |
- close
- close
- close
- close
Senesco Technologies (SNT) |
StreetInsider.com
Nov 23
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NYSE+Delists+Senesco+Technologies+%28SNT%29/7900259.html for the full story.
StreetInsider.com
Nov 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Senesco+Technologies%2C+Inc.+%28SNT%29+Reports+Q3+Loss+of+%240.03/7881950.html for the full story.
StreetInsider.com
Sep 18
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Senesco+Technologies+%28SNT%29+Reports+Fiscal+Year+2012+Financial+Results/7735649.html for the full story.
StreetInsider.com
Sep 13
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Senesco+Tech+%28SNT%29+Doses+First+Patient+in+SNS01-T+Cohort+2/7724420.html for the full story.
Benzinga
Sep 10
Comment
Senesco Technologies(NYSE: SNT)
announced today that the combination of bortezomib (the active component of
VELCADE^® marketed by Millennium, The Takeda Oncology Company) and SNS01-T,
the subject of Senesco's on-going multiple myeloma clinical...
Benzinga
Aug 27
Comment
On August 22, 2012, Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) received a notice from NYSE Regulation, Inc. on behalf of NYSE MKT LLC (the “NYSE MKT”) providing notification that NYSE MKT has determined not...
StreetInsider.com
Aug 13
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Senesco+Tech+%28SNT%29+Reports+Significant+Data+on+Tumor+Reduction+from+SNS01-T+w+Lenalidomide/7652651.html for the full story.
Benzinga
Jul 30
Comment
Senesco Technologies (NYSE: SNT) reported today that it was informed on July 26th that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell...
Benzinga
Jun 4
Comment
Senesco Technologies (NYSE: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical...
Benzinga
Mar 2
Comment
Senesco Technologies, Inc. (NYSE: SNT) announced today that it has entered into a securities purchase agreement
to raise an additional $1.0 million in gross proceeds through the sale of
3,846,154 shares of its common stock. The investor will also...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
